|
US7192584B2
(en)
*
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
JP2005508838A
(ja)
*
|
2001-03-23 |
2005-04-07 |
アフトン コーポレーション |
膵癌の組合せ治療
|
|
US20090191232A1
(en)
*
|
2001-05-04 |
2009-07-30 |
Gevas Philip C |
Combination therapy for the treatment of tumors
|
|
JP2004536835A
(ja)
*
|
2001-07-09 |
2004-12-09 |
アフトン コーポレーション |
肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
|
|
US20060165675A1
(en)
*
|
2002-08-02 |
2006-07-27 |
Richman-Eisenstat Janice Beth |
Modulation of mesenchymal cells via iga-receptors
|
|
JP4689597B2
(ja)
*
|
2003-03-28 |
2011-05-25 |
レセプター バイオロジックス インク． |
ガストリンホルモン免疫アッセイ
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
EP1570858A1
(en)
*
|
2004-03-05 |
2005-09-07 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Monovalent ligand of the FCalphaRi receptor as an anti-inflammatory agent
|
|
EP1730193A2
(en)
*
|
2004-03-29 |
2006-12-13 |
Receptor Biologix, Inc. |
Monoclonal antibodies to gastrin hormone
|
|
KR101333168B1
(ko)
|
2004-09-22 |
2013-11-28 |
리셉터 바이오로직스 인크 |
프로가스트린에 대한 모노클로날 항체
|
|
CA2606081C
(en)
|
2005-04-26 |
2013-09-17 |
Markus M. Heiss |
Combination of the application of antibodies for immunostimulation together with glucocorticoids
|
|
HRP20140338T1
(hr)
|
2005-07-25 |
2014-06-20 |
Emergent Product Development Seattle, Llc |
Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
|
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
|
KR101491700B1
(ko)
|
2007-08-23 |
2015-02-11 |
가부시키가이샤 엘에스아이 메디엔스 |
비특이반응 억제제
|
|
EP2365003A1
(en)
|
2008-04-11 |
2011-09-14 |
Emergent Product Development Seattle, LLC |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
EP2127666A1
(en)
*
|
2008-05-28 |
2009-12-02 |
Drug Discovery Factory B.V. |
Method for the treatment or prophylaxis of chronic inflammatory diseases
|
|
WO2011088219A2
(en)
*
|
2010-01-13 |
2011-07-21 |
The Uab Research Foundation |
Therapeutics and processes for treatment of immune disorders
|
|
EP3165540A1
(en)
|
2010-04-13 |
2017-05-10 |
Celldex Therapeutics, Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
WO2012021512A2
(en)
|
2010-08-10 |
2012-02-16 |
Ecole Polytechnique Federale De Lausanne |
Erythrocyte-binding therapeutics
|
|
US9517257B2
(en)
|
2010-08-10 |
2016-12-13 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
US9850296B2
(en)
|
2010-08-10 |
2017-12-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
EP2465536A1
(en)
*
|
2010-12-14 |
2012-06-20 |
CSL Behring AG |
CD89 activation in therapy
|
|
EP3575794A1
(en)
*
|
2012-02-10 |
2019-12-04 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
|
EP2636684A1
(en)
|
2012-03-09 |
2013-09-11 |
CSL Behring AG |
Prevention of infection
|
|
EP2636681A1
(en)
|
2012-03-09 |
2013-09-11 |
CSL Behring AG |
Process for enriching IgA
|
|
ES2751976T3
(es)
|
2012-03-09 |
2020-04-02 |
Csl Behring Ag |
Composiciones que comprenden inmunoglobulinas de tipo secretor
|
|
KR102717969B1
(ko)
|
2014-02-21 |
2024-10-15 |
에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) |
글리코타겟팅 치료제
|
|
US10946079B2
(en)
|
2014-02-21 |
2021-03-16 |
Ecole Polytechnique Federale De Lausanne |
Glycotargeting therapeutics
|
|
US10046056B2
(en)
|
2014-02-21 |
2018-08-14 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
US10953101B2
(en)
|
2014-02-21 |
2021-03-23 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
CA2980642C
(en)
*
|
2015-03-25 |
2022-09-20 |
Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. |
Anti-cd89 cytotoxic complex
|
|
UY36751A
(es)
|
2015-06-26 |
2017-01-31 |
Novartis Ag |
Anticuerpos de factor xi y métodos de uso
|
|
EP3352760B1
(en)
|
2015-09-21 |
2026-03-11 |
Aptevo Research and Development LLC |
Cd3 binding polypeptides
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
EP3904880A1
(fr)
*
|
2016-09-30 |
2021-11-03 |
Centre national de la recherche scientifique |
Marqueurs membranaires
|
|
US12188935B2
(en)
|
2016-09-30 |
2025-01-07 |
Centre National De La Recherche Scientifique |
Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
|
|
US10610104B2
(en)
|
2016-12-07 |
2020-04-07 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
IL267538B2
(en)
|
2016-12-23 |
2024-05-01 |
Novartis Ag |
Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
|
|
US20210138213A1
(en)
|
2017-03-30 |
2021-05-13 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
WO2018232230A1
(en)
|
2017-06-15 |
2018-12-20 |
Cancer Advances Inc. |
Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
|
|
US12150978B2
(en)
|
2017-06-15 |
2024-11-26 |
Cancer Advances Inc. |
Compositions and methods for preventing tumors and cancer
|
|
US11253579B2
(en)
|
2017-06-16 |
2022-02-22 |
The University Of Chicago |
Compositions and methods for inducing immune tolerance
|
|
JP7009517B2
(ja)
|
2017-06-21 |
2022-01-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
|
|
US11459393B2
(en)
|
2018-04-17 |
2022-10-04 |
Celldex Therapeutics, Inc. |
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
|
|
EA202092723A1
(ru)
|
2018-05-09 |
2021-04-09 |
Зе Юниверсити Оф Чикаго |
Композиции и способы, касающиеся иммунной толерантности
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
US20220249814A1
(en)
|
2018-11-19 |
2022-08-11 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
|
CN121197633A
(zh)
|
2019-12-13 |
2025-12-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
JP7754841B2
(ja)
*
|
2020-04-21 |
2025-10-15 |
ジェイジェイピー バイオロジクス エスピー．ゼット オー．オー． |
ヒト化抗ヒトｃｄ８９抗体及びその使用
|
|
JP2023545099A
(ja)
|
2020-10-08 |
2023-10-26 |
アフィメド ゲーエムベーハー |
三重特異性バインダー
|
|
KR102766045B1
(ko)
*
|
2020-11-06 |
2025-02-10 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합력이 향상된 항체
|
|
KR102855679B1
(ko)
*
|
2020-11-06 |
2025-09-04 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합 항체
|
|
CN116419928A
(zh)
*
|
2020-11-06 |
2023-07-11 |
高丽大学校产学协力团 |
Fcα受体结合抗体
|
|
KR102853685B1
(ko)
*
|
2020-11-06 |
2025-09-01 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합력이 증진된 항체
|
|
CA3216098A1
(en)
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
|
WO2024218512A1
(en)
|
2023-04-19 |
2024-10-24 |
Centessa Pharmaceuticals (Uk) Limited |
Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof
|
|
CN117890576A
(zh)
*
|
2023-12-12 |
2024-04-16 |
深圳市陆为生物技术有限公司 |
一种检测CD89-IgA免疫复合物的试剂、方法及其应用
|
|
WO2025218725A1
(zh)
*
|
2024-04-18 |
2025-10-23 |
徕特康(苏州)生物制药有限公司 |
靶向cd20和cd89的髓细胞衔接子抗体及其用途
|
|
WO2026002175A1
(zh)
*
|
2024-06-27 |
2026-01-02 |
无锡徕特康生物科技有限公司 |
靶向ilt7和cd89的髓细胞衔接子抗体及其用途
|